- Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
-
Rampal R, Kedia S, Wari MN, Madhu D, Singh AK, Tiwari V, Mouli VP, Mohta S, Makharia G, Ahuja V
- KMID: 2515482
- Intest Res.
- 2021 Apr;19(2):232-238.
- doi: 10.5217/ir.2019.09181
Background/Aims: Crohn’s disease (CD) and intestinal tuberculosis (ITB) remain “difficult-to-differentiate” diseases. We have previously documented peripheral blood frequency of CD4+CD25+FOXP3+ T-regulatory cells (Treg) as a biomarker to differentiate CD and... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer
-
Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas , Mouli VP, Kedia S, Dhingra R, Pradhan R, Kumar NS, Yadav DP, Makharia G, Ahuja V
- KMID: 2354969
- Intest Res.
- 2016 Jul;14(3):264-269.
- doi: 10.5217/ir.2016.14.3.264
BACKGROUND/AIMS: Recent data suggest that the incidence of ulcerative colitis (UC) related colorectal cancer (CRC) in India is similar to that of West. The optimum method for surveillance is still... -
- CITED
-
- Close
- SHARE
-
- Close
- High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
-
Agarwal A, Kedia S, Jain S, Gupta V, Bopanna S, Yadav DP, Goyal S, Mouli VP, Dhingra R, Makharia G, Ahuja V
- KMID: 2434161
- Intest Res.
- 2018 Oct;16(4):588-598.
- doi: 10.5217/ir.2018.00023
BACKGROUND/AIMS: The data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk... -
- CITED
-
- Close
- SHARE
-
- Close
